All questionsSpecific populations: Entyvio (vedolizumab), all indications5 questions · 1 sourcePregnancy and breastfeedingCan Entyvio be used during pregnancy?“Available data from the Organization of Teratology Information Specialists (OTIS)/ MotherToBaby ENTYVIO Pregnancy Registry, published literature and pharmacovigilance in pregnant women have not reliably identified an ENTYVIO-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes (see Data). There are risks to the mother and the fetus associated with inflammatory bowel disease in pregnancy (see Clinical Considerations).” (opens the source at this quote in a new tab)CopyFlag“ENTYVIO administered during pregnancy could affect immune responses in the in utero- exposed newborn and infant. The clinical significance of low levels of ENTYVIO in utero- exposed infants is unknown.” (opens the source at this quote in a new tab)CopyFlag“The proportion of major birth defects among live-born infants in patients with UC or CD treated with vedolizumab and patients with UC or CD treated with other biological products was 7.4% (7/94) and 5.6% (4/71), respectively. Overall, there was no evidence of increased risk for major structural birth defects (adjusted RR 1.07, 95% CI: 0.33, 3.52). The methodological limitations of the registry, including small sample size and the non- randomized design, resulted in a limited ability to estimate the risk of major birth defects and other maternal and infant outcomes.” (opens the source at this quote in a new tab)CopyFlagCan Entyvio be used while breastfeeding?“Data from a clinical lactation study show the presence of vedolizumab in human milk. The mean calculated daily infant dosage was 0.02 mg/kg/day orally (see Data). Systemic exposure in a breastfed infant is expected to be low because monoclonal antibodies are largely degraded in the gastrointestinal tract. There are no data on the effects of vedolizumab on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ENTYVIO and any potential adverse effects on the breastfed infant from ENTYVIO or from the underlying maternal condition.” (opens the source at this quote in a new tab)CopyFlagPediatric useCan children use Entyvio?“Safety and effectiveness of ENTYVIO in pediatric patients have not been established.” (opens the source at this quote in a new tab)CopyFlagSpecific populationsIs Entyvio safe and effective for adults 65 and older?“Clinical trials of ENTYVIO did not include sufficient numbers of patients aged 65 and over (72 patients with Crohn’s disease or ulcerative colitis aged 65 and over were treated with ENTYVIO during controlled Phase 3 trials) to determine whether they respond differently from younger adult patients. However, no overall differences in safety or effectiveness were observed between these patients and younger adult patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients.” (opens the source at this quote in a new tab)CopyFlagHas Entyvio been studied in kidney or liver impairment?“Pharmacokinetics of vedolizumab in patients with renal or hepatic insufficiency have not been studied.” (opens the source at this quote in a new tab)CopyFlag“Population pharmacokinetic analysis showed that the severity of disease state, body weight, prior treatment with TNF blocker therapy, age (18 to 78 years), serum albumin, coadministered immunomodulators (including azathioprine, 6-mercaptopurine, methotrexate), and coadministered aminosalicylates did not have a clinically meaningful effect on the pharmacokinetics of ENTYVIO.” (opens the source at this quote in a new tab)CopyFlag